Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Levacetylleucine→

Levacetylleucine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1188-21-2
Molecular formula
C8H15NO3
Molecular weight
173.21 g/mol
Drug class
Acetylated L-leucineneurometabolic therapy for selected inherited neurological disorders
Mechanism of action
The mechanism is not fully established. Acetylated leucine may modulate neuronal energy metabolism, membrane stability and cerebellar network function; no single molecular target is confirmed as the clinical mechanism.
Indications / reported uses
  • Treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and paediatric patients weighing at least 15 kg under the US AQNEURSA indication
  • Treatment of ataxia-telangiectasia in adults and paediatric patients weighing at least 15 kg under the US indication where authorised; verify current label wording for disease-specific use

Sources: US DailyMed — AQNEURSA (levacetylleucine) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Levacetylleucine Environmental Risk Assessment (ERA) (the Levacetylleucine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.